Athenex Announces New England Journal of Medicine Publication of Phase III Data on the Efficacy ...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Athenex Announces New England Journal of Medicine Publication of Phase III Data on the Efficacy ... Athenex, Inc.February 11, 2021 GMT The New England Journal of Medicine published the Phase III trial results on Klisyri®, an anti-proliferative agent that inhibits tubulin polymerization and Src kinase signaling, for the topical treatment of actinic keratosis (AK) of the face or scalp Klisyri®, developed by Athenex, received FDA approval in December 2020 Across two large Phase III randomized control...